Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Galapagos NV Reaffirms FY 2013 Revenue Guidance
Galapagos NV announced that its guidance for fiscal 2013 revenues remains unchanged at EUR160 million.
Latest Developments for Galapagos NV
Latest Key Developments in Biotechnology
- Achaogen Inc announces closing of initial public offering
- IntelliCell Biosciences Inc announces it will file an IND for Osteoarthritis of the Knee in conjunction with the Andrews's Research and Educational Foundation
- Repros Therapeutics Inc allowed to conduct phase 1 and 2 clinical studies of Low Dose Oral Proellex in treatment of Uterine Fibroids and Endometriosis
- Can Fite Biopharma Ltd announces phase II study protocol to treat patients with advanced liver cancer with CF102 has been approved by IRB in Israel
- Share this
- Digg this